Grape King Bio Ltd (TPE:1707)
136.00
-1.00 (-0.73%)
May 13, 2025, 1:35 PM CST
Grape King Bio Revenue
Grape King Bio had revenue of 2.25B TWD in the quarter ending March 31, 2025, a decrease of -4.06%. This brings the company's revenue in the last twelve months to 11.06B, up 2.80% year-over-year. In the year 2024, Grape King Bio had annual revenue of 11.16B with 4.93% growth.
Revenue (ttm)
11.06B
Revenue Growth
+2.80%
P/S Ratio
1.82
Revenue / Employee
22.09M
Employees
501
Market Cap
20.15B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.16B | 524.54M | 4.93% |
Dec 31, 2023 | 10.64B | 244.23M | 2.35% |
Dec 31, 2022 | 10.39B | 592.99M | 6.05% |
Dec 31, 2021 | 9.80B | 630.05M | 6.87% |
Dec 31, 2020 | 9.17B | -70.88M | -0.77% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PharmaEssentia | 11.34B |
Caliway Biopharmaceuticals | 40.47M |
Bora Pharmaceuticals Co., LTD. | 19.25B |
Lotus Pharmaceutical | 19.12B |
Polaris Group | 107.00M |
Oneness Biotech | 117.93M |
Pegavision | 6.69B |
Lumosa Therapeutics | 43.59M |